Royal Bank Of Canada Entera Bio Ltd. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$0.64 - $1.72 $1,920 - $5,160	3,000 New	3,000 $5,000
Q1 2024 May 15, 2024	BUY	$0.64 - $1.72 $1,792 - $4,816	2,800 Added 1400.0%	3,000 $5,000
Q4 2023 Feb 14, 2024	BUY	$0.55 - $0.74 $110 - $148	200 New	200 $0
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.95 $6 - $14	-5 Reduced 0.86%	576 $1,000
Q1 2022 May 16, 2022	BUY	$1.91 - $3.23 $1,109 - $1,876	581 New	581 $2,000
Q4 2021 Feb 14, 2022	SELL	$2.82 - $4.79 $5,341 - $9,072	-1,894 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.43 - $6.29 $8,390 - $11,913	1,894 New	1,894 $9,000

5.34M

2.6K

100

Ticker ENTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,809,900
Market Cap $65.1M
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.